OTCMKTS:RGDXQ Response Genetics (RGDXQ) Stock Price, News & Analysis → “The Stock Market’s Bull Run is Far from Over” -Barrons (From Vertical Research Advisory) (Ad) Free RGDXQ Stock Alerts Add Compare Share Share Today's Range N/A50-Day Range N/A52-Week Range N/AVolumeN/AAverage VolumeN/AMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartFinancialsHeadlinesShort InterestStock AnalysisChartFinancialsHeadlinesShort Interest Get Response Genetics alerts: Email Address Ad Vertical Research Advisory“The Stock Market’s Bull Run is Far from Over” -BarronsBarron's reports that the "stock market's bull run is FAR from over…" And recent economic growth will fuel the price of select stocks in the coming months!Click here for all the details now… About Response Genetics Stock (OTCMKTS:RGDXQ)Response Genetics, Inc., a life sciences company, researches, develops, markets, and sells pharmacogenomic tests for use in the treatment of cancer in the United States, Europe, and internationally. The company offers tests for measuring predictive factors for therapy response in tumor tissue samples. It provides testing services for non-small cell lung cancer, colorectal cancer, gastric and gastroesophageal cancer, melanoma and thyroid cancer, breast cancer, and glioma through its ResponseDX: Lung, ResponseDX: Colon, ResponseDX: Gastric, ResponseDX: Melanoma, ResponseDX: Thyroid, ResponseDX: Breast, ResponseDX: Glioma, and ResponseDX: Tissue of Origin test suites. The company also develops tests for other tumor types; and provides technical component and professional component testing services. It serves community based oncologists, pathologists, physician offices, hospitals, and pharmaceutical companies through its sales force. The company was formerly known as Bio Type, Inc. and changed its name to Response Genetics, Inc. in August 2000. Response Genetics, Inc. was founded in 1999 and is headquartered in Los Angeles, California.Read More Ad Vertical Research Advisory“The Stock Market’s Bull Run is Far from Over” -BarronsBarron's reports that the "stock market's bull run is FAR from over…" And recent economic growth will fuel the price of select stocks in the coming months!Click here for all the details now… RGDXQ Stock News HeadlinesMarch 27, 2024 | msn.comSecurity tightens at RGI Stadium for IPL 2024 matchesMarch 25, 2024 | msn.comStudy with rodents identifies key genes for control of blood pressure and heart rateMarch 29, 2024 | Vertical Research Advisory (Ad)“The Stock Market’s Bull Run is Far from Over” -BarronsBarron's reports that the "stock market's bull run is FAR from over…" And recent economic growth will fuel the price of select stocks in the coming months!March 20, 2024 | tmcnet.comSOPHiA GENETICS Announces First Homologous Recombination Deficiency (HRD) Customer in CanadaMarch 20, 2024 | msn.comStudy maps main genes involved in immune response to infection by dengue virusMarch 14, 2024 | msn.comResearchers find the key to genome-modifying drugs' sensitivity in malignant blood diseasesMarch 6, 2024 | msn.comStudy reveals genetic clusters and biological pathways that may explain differences in type 2 diabetes riskFebruary 28, 2024 | tmcnet.comREVEAL GENOMICS® HER2DX® Genomic Test to Undergo First Prospective Trial as Part of the DEFINITIVE Project, Funded by the European CommissionMarch 29, 2024 | Vertical Research Advisory (Ad)“The Stock Market’s Bull Run is Far from Over” -BarronsBarron's reports that the "stock market's bull run is FAR from over…" And recent economic growth will fuel the price of select stocks in the coming months!February 27, 2024 | msn.comRemote online genetic education programs can spur testing for inherited susceptibility to cancer, study suggestsFebruary 27, 2024 | msn.comGENERATE study: Remote genetic education boosts testing rates for inherited cancer riskFebruary 22, 2024 | msn.comScientists develop a simple blood test to quickly diagnose sarcoidosisFebruary 22, 2024 | msn.comMechanism of Cancer Drug Targeting Tumor Suppressor Genes UnveiledFebruary 22, 2024 | msn.comScientists welcome regulator’s call sorting ‘null segregants’ from GMOsFebruary 21, 2024 | msn.comStudy reveals mechanism of drug targeting protein modification in tumor suppressor genesFebruary 20, 2024 | msn.comAnalysis identifies more than 275 million previously unreported genetic variationsFebruary 12, 2024 | msn.comAndrogen receptor signaling found to upregulate gene driving melanoma severity in menFebruary 7, 2024 | msn.comStudy finds corn genome can gang up on multiple pathogens at onceFebruary 7, 2024 | msn.comNew sex-specific genetic variants for chronic kidney disease identifiedFebruary 5, 2024 | msn.comGenetic testing opens new avenues for cancer diagnoses and treatmentFebruary 2, 2024 | msn.comIdentifying genomics markers to predict radiation sensitivityJanuary 25, 2024 | msn.comRussia fires genetics institute head who claimed humans once lived for 900 yearsJanuary 25, 2024 | msn.comRT-PCR genotyping outperforms whole-genome sequencing in speedy and accurate COVID-19 variant trackingJanuary 23, 2024 | msn.comStudy uncovers 23 new genetic markers linked to kidney health on the X-chromosomeJanuary 15, 2024 | finance.yahoo.comReview Growth Index (RGI): Plastic Surgeons’ Top New Benchmark for Google ReviewsJanuary 10, 2024 | msn.comNewly identified genes for depression may lead to new treatmentsJanuary 10, 2024 | msn.comScientists uncover 13 distinct patterns in DNA mutation risks with implications for cancer evolutionSee More Headlines Receive RGDXQ Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Response Genetics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Today3/29/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Diagnostic substances Sub-IndustryN/A Current SymbolOTCMKTS:RGDXQ Previous SymbolNASDAQ:RGDX CUSIPN/A CIK1124608 Webwww.responsegenetics.com Phone(323) 224-3900Fax323-224-3096Employees96Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable Beta1.96 13 Stocks Institutional Investors Won't Stop BuyingWhich stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.Get This Free Report Key ExecutivesKevin Roy HarrisChief Financial Officer, Director & Vice PresidentKey CompetitorsBG MedicineOTCMKTS:BGMDFluoroPharma MedicalOTCMKTS:FPMIGlobal WholeHealth PartnersOTCMKTS:GWHPHemagen DiagnosticsOTCMKTS:HMGNIpsenOTCMKTS:IPSEYView All Competitors RGDXQ Stock Analysis - Frequently Asked Questions How do I buy shares of Response Genetics? Shares of RGDXQ stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (OTCMKTS:RGDXQ) was last updated on 3/29/2024 by MarketBeat.com Staff From Our PartnersDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsTop Project Outperforms BTC in 2023…Crypto 101 MediaMake This $3 Trade the Instant the Opening Bell RingsMonument Traders Alliance“The Stock Market’s Bull Run is Far from Over” -BarronsVertical Research AdvisoryAI Cracks Open Largest Untapped Energy Reserve on EarthBanyan Hill PublishingThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading AcademyMost important medical advance in 100 yearsThe Oxford ClubBuy this small stock before coming AI Tidal WaveChaikin Analytics Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Response Genetics, Inc Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.